Navigating the Clinical Research Process for Lymphoma
NCT06070246 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-10-06
Summary
Participation in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
This trial will admit a wide range of data on the clinical trial experience of lymphoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future lymphoma patients.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-31
- Primary Completion
- 2025-10-31
- Completion
- 2026-10-31
Countries
- United States
Study Locations
More Related Trials
-
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00324831 ·Status: SUSPENDED ·Phase: PHASE3
-
Testing a Personalize Medication Log for Patients With Lymphoma
NCT02370446 ·Status: COMPLETED
-
Lenalidomide Maintenance Post-debulking in Advanced CTCL
NCT01098656 ·Status: TERMINATED ·Phase: PHASE3
-
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
NCT00064116 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
NCT00003204 ·Status: COMPLETED ·Phase: PHASE3
-
Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
NCT06912529 ·Status: TERMINATED ·Phase: PHASE2
-
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00428142 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
NCT01419795 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
NCT00490529 ·Status: COMPLETED ·Phase: PHASE2
-
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
NCT06526065 ·Status: RECRUITING
-
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
NCT00695786 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00278421 ·Status: COMPLETED ·Phase: PHASE3
-
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
NCT00186394 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
NCT01902862 ·Status: TERMINATED ·Phase: PHASE2
-
Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia
NCT02144623 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).
NCT01021423 ·Status: TERMINATED ·Phase: PHASE3
-
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
NCT03117036 ·Status: RECRUITING
-
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00278408 ·Status: COMPLETED ·Phase: PHASE3
-
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
NCT02856646 ·Status: COMPLETED
-
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
NCT00049413 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
NCT05464823 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
NCT01476787 ·Status: COMPLETED ·Phase: PHASE3
-
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
NCT01318317 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
NCT00186355 ·Status: COMPLETED ·Phase: NA
-
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
NCT00829205 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2